[HTML][HTML] ECM remodeling in hypertensive heart disease

BC Berk, K Fujiwara, S Lehoux - The Journal of clinical …, 2007 - Am Soc Clin Investig
BC Berk, K Fujiwara, S Lehoux
The Journal of clinical investigation, 2007Am Soc Clin Investig
Hypertensive heart disease (HHD) occurs in patients that clinically have both diastolic and
systolic heart failure and will soon become the most common cause of heart failure. Two key
aspects of heart failure secondary to HHD are the relatively highly prevalent LV hypertrophy
and cardiac fibrosis, caused by changes in the local and systemic neurohormonal
environment. The fibrotic state is marked by changes in the balance between MMPs and
their inhibitors, which alter the composition of the ECM. Importantly, the fibrotic ECM impairs …
Hypertensive heart disease (HHD) occurs in patients that clinically have both diastolic and systolic heart failure and will soon become the most common cause of heart failure. Two key aspects of heart failure secondary to HHD are the relatively highly prevalent LV hypertrophy and cardiac fibrosis, caused by changes in the local and systemic neurohormonal environment. The fibrotic state is marked by changes in the balance between MMPs and their inhibitors, which alter the composition of the ECM. Importantly, the fibrotic ECM impairs cardiomyocyte function. Recent research suggests that therapies targeting the expression, synthesis, or activation of the enzymes responsible for ECM homeostasis might represent novel opportunities to modify the natural progression of HHD.
The Journal of Clinical Investigation